Beyond Dopamine: Glutamate as a Target for Future Antipsychotics
Open Access
- 5 July 2012
- journal article
- Published by Wiley in ISRN Pharmacology
- Vol. 2012, 1-9
Abstract
The dopamine hypothesis of schizophrenia remains the primary theoretical framework for the pharmacological treatment of the disorder. Despite various lines of evidence of dopaminergic abnormalities and reasonable efficacy of current antipsychotic medication, a significant proportion of patients show suboptimal treatment responses, poor tolerability, and a subsequent lack of treatment concordance. In recent decades, intriguing evidence for the critical involvement of other neurotransmitter systems in the pathophysiology of schizophrenia has emerged, most notably of dysfunctions within the glutamate pathways. Consequently, the glutamate synapse has arisen as a promising target for urgently needed novel antipsychotic compounds—particularly in regards to debilitating negative and cognitive symptoms poorly controlled by currently available drugs. In this paper, recent findings integrating glutamatergic and dopaminergic abnormalities in schizophrenia and their implications for novel pharmacological targets are discussed. An overview of compounds in various stages of development is given: drugs enhancing NMDA receptor function as well as metabotropic glutamate receptor (mGluR) agonist and positive allosteric modulators (PAMs) are emphasised. Together with other agents more indirectly affecting glutamatergic neurotransmission, their potential future role in the pharmacotherapy of schizophrenia is critically evaluated.Keywords
This publication has 131 references indexed in Scilit:
- Metabotropic glutamate receptors as therapeutic targets for schizophreniaNeuropharmacology, 2012
- Targeting glutamate synapses in schizophreniaTrends in Molecular Medicine, 2011
- Cognitive and symptomatic predictors of functional disability in schizophreniaSchizophrenia Research, 2011
- High dose D-serine in the treatment of schizophreniaSchizophrenia Research, 2010
- Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockadeEuropean Journal of Pharmacology, 2010
- Selective potentiation of the metabotropic glutamate receptor subtype 2 blocks phencyclidine-induced hyperlocomotion and brain activationNeuroscience, 2010
- Deficits in adult prefrontal cortex neurons and behavior following early post-natal NMDA antagonist treatmentPharmacology Biochemistry and Behavior, 2009
- Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophreniaTrends in Pharmacological Sciences, 2009
- Circuit-based framework for understanding neurotransmitter and risk gene interactions in schizophreniaTrends in Neurosciences, 2008
- Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trialNature Medicine, 2007